AI assistant
AMICUS THERAPEUTICS, INC. — Director's Dealing 2019
Jan 17, 2019
31523_dirs_2019-01-17_ec6dc090-38e2-4ee0-9e20-1fef863bce45.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2019-01-15
Reporting Person: Do Hung (Chief Science Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-01-15 | Common Stock | M | 4400 | $2.94 | Acquired | 452713 | Direct |
| 2019-01-15 | Common Stock | M | 3800 | $5.13 | Acquired | 456513 | Direct |
| 2019-01-15 | Common Stock | S | 16600 | $12.00 | Disposed | 439913 | Direct |
| 2019-01-16 | Common Stock | M | 4988 | $2.94 | Acquired | 444901 | Direct |
| 2019-01-16 | Common Stock | M | 30036 | $5.13 | Acquired | 474937 | Direct |
| 2019-01-16 | Common Stock | S | 36669 | $12.05 | Disposed | 438268 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-01-15 | Stock Options (right to buy) | $2.94 | M | 4400 | Disposed | 2024-06-26 | Common Stock (4400) | Direct |
| 2019-01-15 | Stock Options (right to buy) | $5.13 | M | 3800 | Disposed | 2027-01-03 | Common Stock (3800) | Direct |
| 2019-01-16 | Stock Options (right to buy) | $2.94 | M | 4988 | Disposed | 2024-06-26 | Common Stock (4988) | Direct |
| 2019-01-16 | Stock Options (right to buy) | $5.13 | M | 30036 | Disposed | 2027-01-03 | Common Stock (30036) | Direct |
Footnotes
F1: The sale of common stock was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2018.
F2: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.00 to $12.23. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: All of the options were fully vested and exercisable as of January 15, 2019.
F4: These options vest and become exercisable in a series of installments. The first installment, which consists of 25% of the total aggregate number of options granted, vests on January 3, 2018. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments, beginning on February 1, 2018, with the final installment vesting on January 1, 2021.